Studies of animal models of Parkinson disease as well as clinical investigations, have shown that transplantation of fetal DA neurons can relieve the symptoms this disease. However the technical and ethical difficulties in obtaining sufficient and appropriate donor fetal brain tissue have limited the application of this therapy.
These researchers previously demonstrated that mouse embryonic stem cells can differentiate into neurons when cultured under specific conditions. These same culture conditions, technically simple and efficient, were recently applied to primate embryonic stem cells and resulted in the generation of large numbers of DA neurons. In their current JCI study, Jun Takahashi and colleagues generated neurons from monkey embryonic stem cells and exposed these cells to FGF20, a growth factor that is produced exclusively in the area of the brain affected by Parkinson disease and is reported to have a protective effect on DA neurons. The authors observed increased DA neuron development and subsequently transplanted these neurons into monkeys treated with an agent called MPTP, which is considered a primate model for Parkinson disease. These transplanted cells were able to function as DA neurons and diminished Parkinsonian symptoms.
In an accompanying commentary, J. William Langston from the Parkinson's Institute, California, describes this study as a milestone in the development of stem cell technology but cautions that while the observations are encouraging, the reported number of surviving DA neurons was very low, only 1–3% of the cells surviving, well below the estimated number of DA neurons that survive after fetal cell transplants (approximately 10%). While this may be a difference observed between transplantation in monkeys and humans, Langston stresses that it may be necessary for far more DA neurons to survive and for that survival to be long lasting in order to render this approach as a useful therapy in humans.
Langston highlights that "clearly the study reported here will advance research aimed at validating the use of stem cells to treat neurodegenerative disease" and this is most welcome particularly as investigators face yet another presidential moratorium endeavoring to limit the number of human stem cell lines that can be used for future research and treatment.
TITLE: Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model
AUTHOR CONTACT:
Jun Takahashi
Kyoto University Graduate School of Medicine, Kyoto, Japan.
Phone: 81-75-751-3450; Fax: 81-75-752-9501; E-mail: jbtaka@kuhp.kyoto-u.ac.jp.
A PDF of this article this article is available at: http://www.jci.org/cgi/content/full/115/1/102.
ACCOMPANYING COMMENTARY:
TITLE: The promise of stem cells in Parkinson disease
AUTHOR CONTACT:
J. William Langston
Parkinson's Institute, Sunnyvale, California, USA.
Phone: 408-734-2800; Fax: 408-734-8522; E-mail: jwlangston@thepi.org.
A PDF of this article this article is available at: http://www.jci.org/cgi/content/full/115/1/23.
Journal
Journal of Clinical Investigation